BIOCERES CROP SOLUTIONS CORP (BIOX) Fundamental Analysis & Valuation

NASDAQ:BIOX • KYG1117K1141

Current stock price

0.4218 USD
+0 (+1.13%)
At close:
0.4235 USD
+0 (+0.4%)
After Hours:

This BIOX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. BIOX Profitability Analysis

1.1 Basic Checks

  • BIOX had negative earnings in the past year.
  • In the past year BIOX had a positive cash flow from operations.
  • In multiple years BIOX reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: BIOX reported negative operating cash flow in multiple years.
BIOX Yearly Net Income VS EBIT VS OCF VS FCFBIOX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M

1.2 Ratios

  • With a Return On Assets value of -42.75%, BIOX is not doing good in the industry: 92.77% of the companies in the same industry are doing better.
  • The Return On Equity of BIOX (-313.53%) is worse than 92.77% of its industry peers.
  • BIOX has a worse Return On Invested Capital (0.77%) than 68.67% of its industry peers.
Industry RankSector Rank
ROA -42.75%
ROE -313.53%
ROIC 0.77%
ROA(3y)-1.49%
ROA(5y)-1.52%
ROE(3y)-4.41%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
BIOX Yearly ROA, ROE, ROICBIOX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • The Operating Margin of BIOX (0.95%) is worse than 68.67% of its industry peers.
  • BIOX has a better Gross Margin (38.78%) than 81.93% of its industry peers.
  • In the last couple of years the Gross Margin of BIOX has declined.
Industry RankSector Rank
OM 0.95%
PM (TTM) N/A
GM 38.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.17%
GM growth 5Y-3.14%
BIOX Yearly Profit, Operating, Gross MarginsBIOX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BIOX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIOX is destroying value.
  • The number of shares outstanding for BIOX has been increased compared to 1 year ago.
  • The number of shares outstanding for BIOX has been increased compared to 5 years ago.
  • Compared to 1 year ago, BIOX has a worse debt to assets ratio.
BIOX Yearly Shares OutstandingBIOX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
BIOX Yearly Total Debt VS Total AssetsBIOX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • The Debt to FCF ratio of BIOX is 3.20, which is a good value as it means it would take BIOX, 3.20 years of fcf income to pay off all of its debts.
  • BIOX has a better Debt to FCF ratio (3.20) than 87.95% of its industry peers.
  • BIOX has a Debt/Equity ratio of 0.55. This is a neutral value indicating BIOX is somewhat dependend on debt financing.
  • The Debt to Equity ratio of BIOX (0.55) is better than 63.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.2
Altman-Z N/A
ROIC/WACC0.14
WACC5.57%
BIOX Yearly LT Debt VS Equity VS FCFBIOX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 0.90 indicates that BIOX may have some problems paying its short term obligations.
  • With a Current ratio value of 0.90, BIOX is not doing good in the industry: 92.77% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.70 indicates that BIOX may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.70, BIOX is not doing good in the industry: 84.34% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.7
BIOX Yearly Current Assets VS Current LiabilitesBIOX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BIOX Growth Analysis

3.1 Past

  • BIOX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -3272.41%.
  • The Revenue for BIOX has decreased by -30.08% in the past year. This is quite bad
  • The Revenue has been growing by 14.10% on average over the past years. This is quite good.
EPS 1Y (TTM)-3272.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-988.89%
Revenue 1Y (TTM)-30.08%
Revenue growth 3Y0.5%
Revenue growth 5Y14.1%
Sales Q2Q%-30.99%

3.2 Future

  • Based on estimates for the next years, BIOX will show a very strong growth in Earnings Per Share. The EPS will grow by 26.67% on average per year.
  • Based on estimates for the next years, BIOX will show a quite strong growth in Revenue. The Revenue will grow by 11.87% on average per year.
EPS Next Y79.63%
EPS Next 2Y51.42%
EPS Next 3Y39.47%
EPS Next 5Y26.67%
Revenue Next Year-17.52%
Revenue Next 2Y6.62%
Revenue Next 3Y11.13%
Revenue Next 5Y11.87%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BIOX Yearly Revenue VS EstimatesBIOX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BIOX Yearly EPS VS EstimatesBIOX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 1

More info and screens

Find the best growth stocksShow best growing peers

6

4. BIOX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BIOX. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 1.80, which indicates a rather cheap valuation of BIOX.
  • 100.00% of the companies in the same industry are more expensive than BIOX, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of BIOX to the average of the S&P500 Index (22.51), we can say BIOX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 1.8
BIOX Price Earnings VS Forward Price EarningsBIOX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as BIOX.
  • 100.00% of the companies in the same industry are more expensive than BIOX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 0.36
EV/EBITDA 12.16
BIOX Per share dataBIOX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • BIOX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • BIOX's earnings are expected to grow with 39.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.42%
EPS Next 3Y39.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIOX Dividend Analysis

5.1 Amount

  • BIOX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOX Fundamentals: All Metrics, Ratios and Statistics

BIOCERES CROP SOLUTIONS CORP

NASDAQ:BIOX (3/26/2026, 8:00:02 PM)

After market: 0.4235 +0 (+0.4%)

0.4218

+0 (+1.13%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)03-13
Earnings (Next)N/A
Inst Owners31.69%
Inst Owner Change0.92%
Ins Owners0.68%
Ins Owner ChangeN/A
Market Cap26.78M
Revenue(TTM)285.07M
Net Income(TTM)-239.56M
Analysts43.33
Price Target2.04 (383.64%)
Short Float %1.87%
Short Ratio0.91
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP-0.03%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-137.16%
Min EPS beat(2)-212.04%
Max EPS beat(2)-62.27%
EPS beat(4)1
Avg EPS beat(4)-300.6%
Min EPS beat(4)-1015.03%
Max EPS beat(4)86.93%
EPS beat(8)1
Avg EPS beat(8)-312.5%
EPS beat(12)2
Avg EPS beat(12)-105.66%
EPS beat(16)2
Avg EPS beat(16)-119.1%
Revenue beat(2)0
Avg Revenue beat(2)-20.37%
Min Revenue beat(2)-24.73%
Max Revenue beat(2)-16.01%
Revenue beat(4)0
Avg Revenue beat(4)-20.56%
Min Revenue beat(4)-34.42%
Max Revenue beat(4)-7.07%
Revenue beat(8)0
Avg Revenue beat(8)-18.11%
Revenue beat(12)2
Avg Revenue beat(12)-11.33%
Revenue beat(16)5
Avg Revenue beat(16)-1.92%
PT rev (1m)0%
PT rev (3m)-51.02%
EPS NQ rev (1m)41.18%
EPS NQ rev (3m)59.46%
EPS NY rev (1m)0%
EPS NY rev (3m)45.45%
Revenue NQ rev (1m)-7.63%
Revenue NQ rev (3m)-9.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.8
P/S 0.09
P/FCF 0.36
P/OCF 0.33
P/B 0.35
P/tB N/A
EV/EBITDA 12.16
EPS(TTM)-0.92
EYN/A
EPS(NY)0.23
Fwd EY55.62%
FCF(TTM)1.18
FCFY279.8%
OCF(TTM)1.29
OCFY305.77%
SpS4.49
BVpS1.2
TBVpS-0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.75%
ROE -313.53%
ROCE 1.17%
ROIC 0.77%
ROICexc 0.81%
ROICexgc 1.86%
OM 0.95%
PM (TTM) N/A
GM 38.78%
FCFM 26.28%
ROA(3y)-1.49%
ROA(5y)-1.52%
ROE(3y)-4.41%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.17%
GM growth 5Y-3.14%
F-Score4
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.2
Debt/EBITDA 2.04
Cap/Depr 38.63%
Cap/Sales 2.44%
Interest Coverage 0.2
Cash Conversion 395.37%
Profit Quality N/A
Current Ratio 0.9
Quick Ratio 0.7
Altman-Z N/A
F-Score4
WACC5.57%
ROIC/WACC0.14
Cap/Depr(3y)96.4%
Cap/Depr(5y)121.83%
Cap/Sales(3y)4.91%
Cap/Sales(5y)4.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3272.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-988.89%
EPS Next Y79.63%
EPS Next 2Y51.42%
EPS Next 3Y39.47%
EPS Next 5Y26.67%
Revenue 1Y (TTM)-30.08%
Revenue growth 3Y0.5%
Revenue growth 5Y14.1%
Sales Q2Q%-30.99%
Revenue Next Year-17.52%
Revenue Next 2Y6.62%
Revenue Next 3Y11.13%
Revenue Next 5Y11.87%
EBIT growth 1Y-91.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1110.35%
FCF growth 3YN/A
FCF growth 5Y38.53%
OCF growth 1Y176.61%
OCF growth 3YN/A
OCF growth 5Y34.31%

BIOCERES CROP SOLUTIONS CORP / BIOX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BIOCERES CROP SOLUTIONS CORP (BIOX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BIOX.


Can you provide the valuation status for BIOCERES CROP SOLUTIONS CORP?

ChartMill assigns a valuation rating of 6 / 10 to BIOCERES CROP SOLUTIONS CORP (BIOX). This can be considered as Fairly Valued.


How profitable is BIOCERES CROP SOLUTIONS CORP (BIOX) stock?

BIOCERES CROP SOLUTIONS CORP (BIOX) has a profitability rating of 2 / 10.


Can you provide the financial health for BIOX stock?

The financial health rating of BIOCERES CROP SOLUTIONS CORP (BIOX) is 3 / 10.